Cytosorbents (CTSO) Operating Leases (2018 - 2026)

Cytosorbents (CTSO) has reported Operating Leases for 9 consecutive years, with $11.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 4.83% year-over-year to $11.6 million; the trailing twelve-month figure through Jun 2026 stood at $11.6 million (down 4.83% YoY), and the FY2025 full-year result was $11.9 million, down 4.35% from the prior year.
• Operating Leases declined to $11.6 million in Q2 2026 per CTSO's latest filing, from $11.8 million in the prior quarter.
• Across five years, Operating Leases topped out at $13.7 million in Q1 2022 and bottomed at $11.6 million in Q2 2026.
• Historically, Operating Leases has averaged $12.7 million across 5 years, with a median of $12.8 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Operating Leases soared 1378.35% in 2022, then decreased 6.57% in 2025.
• Over 5 years, Operating Leases stood at $13.3 million in 2022, then slipped by 2.67% to $12.9 million in 2023, then dropped by 3.51% to $12.4 million in 2024, then declined by 4.35% to $11.9 million in 2025, then fell by 2.58% to $11.6 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $11.6 million, $11.8 million, and $11.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.